Related Experiment Video

Updated: Apr 28, 2026

Monitoring GPCR-β-arrestin1/2 Interactions in Real Time Living Systems to Accelerate Drug Discovery
08:21

Monitoring GPCR-β-arrestin1/2 Interactions in Real Time Living Systems to Accelerate Drug Discovery

Published on: June 28, 2019

6.2K

GRAPPA 2013 basic/translational/clinical science update: comorbidity monitoring

Wolf-Henning Boehncke1

  • 1From the Department of Dermatology, Geneva University Hospital, Geneva, Switzerland.W-H. Boehncke, MD. wolf-henning.boehncke@hcuge.ch.

The Journal of Rheumatology
|June 3, 2014
PubMed

Insights

Psoriatic disease significantly increases cardiovascular risk. New screening guidelines are being adapted for dermatologists and rheumatologists to improve cardiovascular risk factor management in patients with psoriatic disease.

Area of Science:

  • Dermatology and Rheumatology
  • Cardiovascular Medicine
  • Public Health

Background:

  • Psoriatic disease is linked to a higher risk of cardiovascular disease.
  • Existing cardiovascular risk factor screening guidelines are often specialized and not widely used in routine dermatology or rheumatology practice.

Purpose of the Study:

  • To adapt existing cardiovascular risk factor screening guidelines for dermatologists and rheumatologists.
  • To improve the management of cardiovascular risk in patients with psoriatic disease.

Main Methods:

  • Reviewing current cardiovascular risk factor screening guidelines.
  • Developing adapted checklists and algorithms for dermatologists and rheumatologists.
  • Planning for evaluation of practicability and performance of the new tools.

Main Results:

  • Guidelines are being adapted for non-specialist use.
  • Checklists and algorithms are under development.
  • Future evaluation of the tools is planned.

Conclusions:

  • Adapting cardiovascular screening guidelines for dermatologists and rheumatologists is crucial.
  • Improved screening can lead to better cardiovascular risk management in psoriatic disease patients.

Keywords:
CARDIOVASCULAR RISKCOMORBIDITIESMORTALITYMYOCARDIAL INFARCTIONPSORIASISSCREENING

More Related Videos

Implementation of a Real-Time Psychosis Risk Detection and Alerting System Based on Electronic Health Records using CogStack07:31

Implementation of a Real-Time Psychosis Risk Detection and Alerting System Based on Electronic Health Records using CogStack

Published on: May 15, 2020

8.3K
Tracking Drug-induced Changes in Receptor Post-internalization Trafficking by Colocalizational Analysis07:48

Tracking Drug-induced Changes in Receptor Post-internalization Trafficking by Colocalizational Analysis

Published on: July 3, 2015

8.2K

Related Concept Videos

Therapeutic Drug Monitoring: Overview and Classification01:16

Therapeutic Drug Monitoring: Overview and Classification

Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...
638
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
429
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.7K
Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
8.5K
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
119
Pharmacogenetics and Pharmacogenomics: Overview01:29

Pharmacogenetics and Pharmacogenomics: Overview

Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
248